JP7441213B2 - エストロゲン受容体陽性乳癌の治療のための併用療法 - Google Patents

エストロゲン受容体陽性乳癌の治療のための併用療法 Download PDF

Info

Publication number
JP7441213B2
JP7441213B2 JP2021513996A JP2021513996A JP7441213B2 JP 7441213 B2 JP7441213 B2 JP 7441213B2 JP 2021513996 A JP2021513996 A JP 2021513996A JP 2021513996 A JP2021513996 A JP 2021513996A JP 7441213 B2 JP7441213 B2 JP 7441213B2
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
compound
therapeutic agent
breast cancer
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021513996A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2020053664A5 (https=
JP2022500423A5 (https=
JP2022500423A (ja
Inventor
エリック・カンポー
オレーシャ・カレンコ
エドワード・ティ・エイチ・バン・ダー・ホースト
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zenith Epigenetics Ltd
Original Assignee
Zenith Epigenetics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zenith Epigenetics Ltd filed Critical Zenith Epigenetics Ltd
Publication of JP2022500423A publication Critical patent/JP2022500423A/ja
Publication of JPWO2020053664A5 publication Critical patent/JPWO2020053664A5/ja
Publication of JP2022500423A5 publication Critical patent/JP2022500423A5/ja
Application granted granted Critical
Publication of JP7441213B2 publication Critical patent/JP7441213B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021513996A 2018-09-13 2019-09-13 エストロゲン受容体陽性乳癌の治療のための併用療法 Active JP7441213B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862730837P 2018-09-13 2018-09-13
US62/730,837 2018-09-13
PCT/IB2019/001035 WO2020053664A1 (en) 2018-09-13 2019-09-13 Combination therapy for the treatment of estrogen-receptor positive breast cancer

Publications (4)

Publication Number Publication Date
JP2022500423A JP2022500423A (ja) 2022-01-04
JPWO2020053664A5 JPWO2020053664A5 (https=) 2022-09-22
JP2022500423A5 JP2022500423A5 (https=) 2022-09-22
JP7441213B2 true JP7441213B2 (ja) 2024-02-29

Family

ID=69777646

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021513996A Active JP7441213B2 (ja) 2018-09-13 2019-09-13 エストロゲン受容体陽性乳癌の治療のための併用療法

Country Status (8)

Country Link
US (1) US20220047563A1 (https=)
EP (1) EP3849550B1 (https=)
JP (1) JP7441213B2 (https=)
CN (1) CN112912078B (https=)
CA (1) CA3110788A1 (https=)
ES (1) ES2993363T3 (https=)
TW (1) TWI841598B (https=)
WO (1) WO2020053664A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI882964B (zh) 2018-09-13 2025-05-11 大陸商恒翼生物醫藥（上海）股份有限公司 Bet 溴結構域(bromodomain)抑制劑之固體形式之製備方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523259A (ja) 2013-06-21 2016-08-08 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． 新規の二環式ブロモドメイン阻害剤
WO2017015027A1 (en) 2015-07-20 2017-01-26 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015505562A (ja) * 2012-01-31 2015-02-23 ノバルティス アーゲー Ｒｔｋ阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
WO2014128655A1 (en) * 2013-02-25 2014-08-28 Aurigene Discovery Technologies Limited Substituted imidazo[4,5-c]quinoline derivatives as bromodomain inhibitors
JP6553632B2 (ja) * 2013-11-18 2019-07-31 フォーマ セラピューティクス，インコーポレイテッド Ｂｅｔブロモドメイン阻害剤としてのテトラヒドロキノリン組成物
WO2016203335A1 (en) * 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
WO2018097977A1 (en) * 2016-11-22 2018-05-31 Gilead Sciences, Inc. Crystalline forms of a phosphate complex of a bet inhibitor
WO2018106444A1 (en) * 2016-12-06 2018-06-14 Gilead Sciences, Inc. Treatment of breast cancer by concomitant administration of a bromodomain inhibitor and a second agent
WO2018106433A1 (en) * 2016-12-06 2018-06-14 Gilead Sciences, Inc. Treatment of prostate cancer by concomitant administration of a bromodomain inhibitor and a second agent
EP3758753A1 (en) * 2018-02-27 2021-01-06 Pfizer Inc Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016523259A (ja) 2013-06-21 2016-08-08 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． 新規の二環式ブロモドメイン阻害剤
WO2017015027A1 (en) 2015-07-20 2017-01-26 Mayo Foundation For Medical Education And Research Methods and materials for treating cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Annals of Oncology，2017年，28，pp.1776-1787
Cancer Discovery，2018年01月，pp.24-36
Cancer Res，2018年，78（4_Supplement)，P3-06-07
Cell Research，2014年，24，pp.809-819
https://www.zenithepigenetics.com/upload/media_element/36/01/2015-aacr-eortc-poster.pdf［検索日：２０２３年８月２日］
Oncotarget，2016年，7(34)， pp.54120-54136
Targeted Oncology，2018年08月22日，14:1-12

Also Published As

Publication number Publication date
TW202023552A (zh) 2020-07-01
EP3849550A1 (en) 2021-07-21
EP3849550B1 (en) 2024-08-07
WO2020053664A8 (en) 2020-05-07
JP2022500423A (ja) 2022-01-04
CN112912078A (zh) 2021-06-04
TWI841598B (zh) 2024-05-11
ES2993363T3 (en) 2024-12-27
CA3110788A1 (en) 2020-03-19
WO2020053664A1 (en) 2020-03-19
EP3849550A4 (en) 2022-06-01
CN112912078B (zh) 2023-04-04
US20220047563A1 (en) 2022-02-17

Similar Documents

Publication Publication Date Title
JP7688578B2 (ja) メチオニンアデノシルトランスフェラーゼ２ａインヒビターとしての２－オキソキナゾリン誘導体
AU2018222073B2 (en) O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof
WO2020259432A1 (zh) Kras-g12c抑制剂
CA3152674A1 (en) Pyrazole derivatives for fgfr inhibitor and preparation method thereof
KR20130129244A (ko) 치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도
JP6109880B2 (ja) 三環式アザインドール
JP2014530243A (ja) Ａｒｒｙ−３８０の多形体、選択的ｈｅｒｂ２阻害剤、およびそれらを含有する薬学的組成物
JP2020527173A (ja) ヒストン脱アセチル化酵素１および／または２（ｈｄａｃ１−２）の選択的阻害剤としての新規なヘテロアリールアミド誘導体
MX2010013842A (es) Naftiridinonas como inhibidores de aurora cinasa.
CA3114987A1 (en) Multi-substituted pyridone derivatives and medical use thereof
TW202214603A (zh) 一種噠嗪類衍生物游離鹼晶型及其製備方法和應用
CN116323590A (zh) 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用
CN103965174B (zh) 含有锌结合基的喹唑啉基egfr酪氨酸激酶抑制剂
AU2024205090A1 (en) Methods of use for trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors
WO2023143147A1 (zh) 一种哒嗪并吡啶酮类化合物、其药物组合物及应用
JP7441214B2 (ja) 前立腺がんの治療のための併用療法
JP7441213B2 (ja) エストロゲン受容体陽性乳癌の治療のための併用療法
WO2024235289A1 (zh) 用于egfr蛋白降解的化合物及其用途
WO2023134374A1 (zh) 一类嘧啶并杂环类化合物、制备方法和用途
HK40053731A (en) Combination therapy for the treatment of estrogen-receptor positive breast cancer
WO2025119352A1 (zh) 一种并环类mat2a抑制剂、包含其的药物组合物及其应用
HK40053354B (en) Combination therapy for the treatment of prostate cancer
HK40053354A (en) Combination therapy for the treatment of prostate cancer
WO2024240108A1 (zh) 一种芳基脲类parp1抑制剂、其制备方法及用途
CN116554166A (zh) 一种哒嗪并吡啶酮类化合物、其药物组合物及应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220913

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220913

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230804

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231207

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240130

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240216

R150 Certificate of patent or registration of utility model

Ref document number: 7441213

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150